`1- Case 3:13—cv—OOO91—MLC—DEA Document 26 Filed 05/15/13 Page 1 of 3 Page|D: 179
`
`UNITED STATES DISTRICT COURT
`FOR THE D~ISTR,I.CT OF NEW JERSEY
`
`Civil Action No. 1 1-2317 (JAP-DEA)
`I
`'
`
`Civil Action No. l I-04275 (JAP-DEA)
`
`Civil Action No. 11-06348 (JAP-DEA)
`
`Civil Action No. 13-00091 (JAP)(DEA)
`
`ASTRAZENECA AB, ASTRAZENEC/\f
`LP, and ‘POZEN INC.,
`_
`I
`
`:
`:
`:
`:
`I
`'
`v,
`DR. REDDY’S LABO.RA.TORI.ES INC. and:
`
`Plaintiffs,
`
`DR. REDDY’S LABORATORIES [.TD.,
`Defendémtsp
`
`'
`.
`
`A
`
`ASTRAZENECA AB, ASTRAZENECA :
`LP, KB]-E INC, and POZEN INC.,
`'
`Plaintiffs,"
`
`v.
`
`LUPIN LTD. and LUPIN
`
`PHARMACEUTICALS jlNC.,
`Defendants.
`
`ASTRAZENECA AB, ASTRAZENECA
`LP, KB]-E INC, and POZEN 1NC.,
`Plaintiffs.
`
`v.
`
`.
`
`ANCHEN .P.HAR.MA.C.EUTlCA.LS, lNC.,.
`-
`Defendants)
`
`ASTRAZENECA AB, ASTRAZENECA ’
`LP, and POZEN INC.',
`’
`‘Plaintiffs,
`
`.
`
`:
`'
`
`.
`
`:
`'
`
`:
`-
`'v_.j
`DR. REDDY’S LABORATORIES INC. and:
`
`DR. REDDY’S LABORATORIES LTD,
`
`:
`
`Defendants.
`
`STIPULATEHD CONSENT ORDER
`
`WHEREAS, Plaintiffs ASTRAZENECA AB, ASTRAZENECA LP, and POZEN
`
`INC. have filed AsI“raZerzeca AB, A.s'traZe71eca LP, and Pozen Inc., v. Dr. Reddy’s
`
`Laboratories Inc. ana’.Dr. .Reddy’s Laboratories Ltd, Civil Action. No. 1 1-2317 (JAP-
`
`DEA) (“AstraZeneca v. DRL I”), allcgingginter alia, infringement of U.S. Patent Nos.
`
`5,714,504, 6,369,085, 6,875,872, 6,926,907, 7,4l 1,070, and 7,745,466, which are listed
`
`in the Orange Book for Plaintiffs’ VImOV0®pt'()duCt;
`
`R E C E I V E D
`
`92307lv2
`
`MAY 14 2013
`
`AT 8:30_j_______,_l‘.A
`WILLIAM T. WALSH
`CLERK
`
`
`
`Case 3:13-cv-00091-MLC-DEA Document 26 Filed 05/15/13 Page 2 of 3 PageID: 180
`Case 3:13—cv—OOO91—MLC—DEA Document 26 Filed 05/15/13 Page 2 of 3 Page|D: 180
`
`WHEREAS, Plaintiffs ASTRAZEN ECA AB, ASTRAZENECA LP, and POZEN
`
`INC. have filed As/raZeneca AB, AstraZeneca LP, and Pozen Inc., v. Lupin Ltd. and
`
`Lupin Pharmaceuticals 1110., Civil Action No. 11-4275 (JAP-DEA) (“Astraleneca v.
`
`Lupin”), alleging, inter alia. infringement vofU.S. Patent Nos. 5,714,504, 6,369,085,
`6,875,872, 6,926,907, 7,41 1,070, and 7,745,466, which are listed in the Orange Book for
`
`Plaintiffs’ Vimovo® product;
`
`I
`
`WHEREAS, Plaintiffs ASTRAZE_N'ECA AB, ASTRAZENECA LP, and POZEN
`INC. have filed A.s'traZeneca AB, A.s'traZeneca
`and Pozen Inc., v. Anchen
`
`Pharmaceuticals, Inc., Civil Action No. 1 l-06348 (JAP-DEA) (“Astrazeneca v.
`
`Anchen”), alleging, inter alia, infringement of U.S. Patent Nos. 6,369,085, 6,926,907,
`
`7,41 1,070, and 7,745,466, which are listed in the Orange Book for Plaintiffs’ Vimovo®
`
`product;
`
`WHEREAS, Plaintiffs ASTRAZBNECA AB, ASTRAZENECA LP, and POZEN
`
`INC. have filed AstraZenecaAB. AStraZeneca LP, and Pozen Inc., v. Dr. Reddy’s
`
`Laboratories Inc. and Dr. Reddy’s Laboratories Ltd.-, Civil Action No, 13-00091 (JAP-
`
`DEA) (“Astrazeneca v. DRL 11”), alleging, inter alia, infringement of U.S. Patent Nos.
`
`5,714,504, 6,369,085, 6,926,907, _7,41.1.,070,.and 7,745,466, which are listed in the
`Orange Book for Plaimiffs’ Vimovo® product;
`
`WHEREAS, the Courtlpreviously consolidated Aslr_aZeneca v. DRL I with
`
`AstraZeneca v. Lupin for discovery purposes (DE. 41), and subsequently consolidated
`
`AstraZeneca v. Aachen with the consolidated AstraZeneca v. D_RL I with AsI’raZeneca v.
`
`Lupin actions for discovery purposes (D13. 82),
`
`92307lv2
`
`
`
`Case 3:13-cv-00091-MLC-DEA Document 26 Filed 05/15/13 Page 3 of 3 PageID: 181
`. Case 3:13—cv—OOO91—MLC—DEA Document 26 Filed 05/15/13 Page 3 of 3 Page|D: 181
`
`I
`
`WHEREAS, Dr. Reddy’s Laboratories inc. and Dr. Reddy’s Laboratories Ltd.
`
`seeks consolidation, for discovery purposes, of Asl1'aZeneca v. DRL 11 with AstraZeneca
`
`v. DRL I. AstraZcm*c'a v. Lupin and /lstraZeneca v. Aachen, and all other parties in each
`of these actions consents to such consolidation and further agree that proceedings,
`
`submissions and findings from DRL I will be integrated individually or otherwise into
`
`DRL Has the parties will later agree or the Court will decide;
`WHEREAS; the parties further agree that the propriety of consolidating any
`
`combination of these actions for pretrial and trial purposes shall be considered at such
`
`time as may be appropriate;
`
`THEREFORE, these matters, having come before the Court on the joint
`
`application of the parties for the entry of this Stipulated Consent Order, and for good
`
`cause shown:
`
`IT IS on this
`
`day of May, 201 3,
`
`ORDERED that A.<itraZeneca v. DRL II (1 3-cv—O009l) be consolidated with
`
`A.straZeneca v. DRL I_, /1straZe/vecia v. iLu/Jin and Aslraleneca v. Anchen for discovery
`
`purposes; and it is
`
`FURTHER ORDERED that all future filings and submissions to the Court shall
`
`be made in AstraZeneca v. DRL 1 under Civil Action No. l l-2317 until further Order of
`
`
` DOUGLAS '
`
`PERT
`
`United State
`
`H. istrate Judge
`
`the Court.
`
`.
`
`92307lv2